DK1140034T3 - Formulering af divalproex-natrium med kontrolleret frigivelse - Google Patents

Formulering af divalproex-natrium med kontrolleret frigivelse

Info

Publication number
DK1140034T3
DK1140034T3 DK99968104T DK99968104T DK1140034T3 DK 1140034 T3 DK1140034 T3 DK 1140034T3 DK 99968104 T DK99968104 T DK 99968104T DK 99968104 T DK99968104 T DK 99968104T DK 1140034 T3 DK1140034 T3 DK 1140034T3
Authority
DK
Denmark
Prior art keywords
controlled release
divalproex sodium
sodium formulation
release divalproex
formulation
Prior art date
Application number
DK99968104T
Other languages
English (en)
Inventor
Yihong Qui
Richard P Poska
Howard S Cheskin
J Daniel Bollinger
Kevin R Engh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/216,650 external-priority patent/US6419953B1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK1140034T3 publication Critical patent/DK1140034T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99968104T 1998-12-18 1999-12-09 Formulering af divalproex-natrium med kontrolleret frigivelse DK1140034T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/216,650 US6419953B1 (en) 1998-12-18 1998-12-18 Controlled release formulation of divalproex sodium
US12155799P 1999-02-25 1999-02-25
PCT/US1999/029204 WO2000037055A1 (en) 1998-12-18 1999-12-09 Controlled release formulation of divalproex sodium

Publications (1)

Publication Number Publication Date
DK1140034T3 true DK1140034T3 (da) 2004-03-08

Family

ID=26819594

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968104T DK1140034T3 (da) 1998-12-18 1999-12-09 Formulering af divalproex-natrium med kontrolleret frigivelse

Country Status (25)

Country Link
EP (1) EP1140034B1 (da)
JP (1) JP2003513882A (da)
KR (1) KR20010101295A (da)
CN (1) CN1335769A (da)
AR (1) AR021443A1 (da)
AT (1) ATE254907T1 (da)
AU (1) AU2478900A (da)
BG (1) BG105665A (da)
BR (1) BR9916361A (da)
CA (1) CA2330480C (da)
CO (1) CO5160287A1 (da)
CZ (1) CZ20012201A3 (da)
DE (1) DE69913197T2 (da)
DK (1) DK1140034T3 (da)
ES (1) ES2212667T3 (da)
HK (1) HK1043043B (da)
HU (1) HUP0105463A3 (da)
IL (1) IL143407A0 (da)
NO (1) NO20012986L (da)
PL (1) PL356899A1 (da)
PT (1) PT1140034E (da)
SI (1) SI20624A (da)
SK (1) SK8252001A3 (da)
TW (1) TW585788B (da)
WO (1) WO2000037055A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020025341A1 (en) * 1998-12-18 2002-02-28 Yihong Qiu Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040005357A1 (en) * 2002-07-03 2004-01-08 Sherman Bernard Charles Extended-release tablets comprising divalproex sodium
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
EP1603540A2 (en) * 2003-03-14 2005-12-14 Nirmal Mulye A process for preparing sustained release tablets
HUP0301537A3 (en) * 2003-06-03 2005-07-28 Egis Gyogyszergyar Nyilvanosan Deramcyclane fumarate tablets and process for producing them
US7713550B2 (en) 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006025029A2 (en) * 2004-08-31 2006-03-09 Ranbaxy Laboratories Limited Extended release composition of divalproex
AU2006209212B2 (en) * 2005-01-26 2011-02-17 Elan Pharma International Limited Controlled release compositions comprising an antipsychotic agent
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
US8952060B2 (en) * 2009-05-12 2015-02-10 Amorepacific Corporation Composition for preventing hair loss or for stimulating hair growth
WO2012121862A2 (en) * 2011-02-17 2012-09-13 University Of Florida Research Foundation Valproic acid derivative compounds
CN102138911B (zh) * 2011-03-28 2012-12-12 孙卫东 一种双丙戊酸钠缓释片及其制备方法
CN102895201B (zh) * 2011-07-26 2014-09-10 北大方正集团有限公司 丙戊酸半钠片剂及其制备方法
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
CN105012264B (zh) * 2014-04-16 2019-11-29 四川科瑞德制药股份有限公司 丙戊酸钠缓释片及其制备工艺和用途
CN106389368B (zh) * 2015-07-29 2021-11-12 四川科瑞德制药股份有限公司 一种丙戊酸钠缓释制剂及其制备工艺和用途
CN105456218A (zh) * 2015-12-07 2016-04-06 黑龙江省智诚医药科技有限公司 一种丙戊酸镁缓释片及其制备方法
CN107028907B (zh) * 2016-02-04 2021-05-14 成都康弘药业集团股份有限公司 一种双丙戊酸钠缓释片
CN114681419A (zh) * 2020-12-28 2022-07-01 湖南省湘中制药有限公司 一种丙戊酰胺缓释片的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IL96311A (en) * 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
TW224049B (da) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
TW222585B (da) * 1992-09-11 1994-04-21 Hoechst Ag
JP3552285B2 (ja) * 1993-08-03 2004-08-11 三菱化学株式会社 経口コレステロール低下剤
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity

Also Published As

Publication number Publication date
SI20624A (sl) 2002-02-28
SK8252001A3 (en) 2001-12-03
JP2003513882A (ja) 2003-04-15
HUP0105463A2 (hu) 2002-05-29
NO20012986D0 (no) 2001-06-15
CZ20012201A3 (cs) 2001-09-12
PL356899A1 (en) 2004-07-12
ES2212667T3 (es) 2004-07-16
NO20012986L (no) 2001-08-15
DE69913197T2 (de) 2004-09-02
BG105665A (bg) 2002-03-29
PT1140034E (pt) 2004-03-31
IL143407A0 (en) 2002-04-21
AU2478900A (en) 2000-07-12
CA2330480A1 (en) 2000-06-29
AR021443A1 (es) 2002-07-17
ATE254907T1 (de) 2003-12-15
WO2000037055A1 (en) 2000-06-29
BR9916361A (pt) 2002-11-05
DE69913197D1 (de) 2004-01-08
CO5160287A1 (es) 2002-05-30
CA2330480C (en) 2002-05-21
HK1043043B (zh) 2004-09-10
TW585788B (en) 2004-05-01
KR20010101295A (ko) 2001-11-14
HUP0105463A3 (en) 2003-03-28
HK1043043A1 (en) 2002-09-06
EP1140034B1 (en) 2003-11-26
EP1140034A1 (en) 2001-10-10
CN1335769A (zh) 2002-02-13

Similar Documents

Publication Publication Date Title
DK1140034T3 (da) Formulering af divalproex-natrium med kontrolleret frigivelse
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
DK1140105T3 (da) Galantaminpræparat med styret frigivelse
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
AR026045A1 (es) Formulaciones de liberacion prolongada de derivados de eritromocina
NO20021540L (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
NO20012636D0 (no) Kontrollert frigivelsesformulering som omfatter GNRH-II
DK0746310T3 (da) Præparat med styret afgivelse
DK1109558T3 (da) Ranolazinformuleringer med langvarig frigivelse
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
ATE269075T1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
DK1600154T3 (da) Osmotisk doseringsform med forlænget frigivelse
AR027907A1 (es) Composicion de liberacion controlada
DK0880892T3 (da) Midler med reguleret frigivelse
NO20002126D0 (no) Formulering med forlenget frigjøring
DK1142477T3 (da) Sammensætninger med reguleret frigivelse
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
DK1218096T3 (da) Mikrokapsler med variabel frisætning
DE19983627T1 (de) Knoblauch-Formulierungen mit kontrollierter Freisetzung
ATE217021T1 (de) Präparationsmittel
NO20021452D0 (no) Orale kontrollerte frigivelsesformuleringer
NO984035D0 (no) Farmas°ytiske formuleringer med sakte frigivelse inneholdende mizolastin
NO20003677D0 (no) Langvarig frigivelses tigabim formuleringer med reduserte bivirkninger
SE9802197D0 (sv) Formulations of busulphan
NO971030L (no) Preparat med langvarig frigjöring